Clinical Trial 44156

Aventura, FL 33180


Summary:

The ACeD Study is looking for volunteers with celiac disease to participate in a phase 1 clinical trial testing the investigational drug KAN-101.

 

KAN-101 targets the immune cells that drive celiac disease and leaves the otherwise healthy components of the immune system intact.  KAN-101 acts by re-educating T cells, or tolerizing them, so they do not respond to gluten antigens. 

 

KAN-101 may help patients with celiac disease without interfering with the natural protective functions of the immune system. The goal of this study is to evaluate the safety and tolerability of single or multiple doses of the investigational drug KAN-101 in subjects with celiac disease. This study will also measure how the body responds to the study drug.


Qualified Participants Must:

• 18-70 years old
• Biopsy-confirmed celiac disease
• On a gluten-free diet for at least the last 12 months


Qualified Participants May Receive:

Compensation available.

 


Clinical trials are medical research studies designed to test the safety and/or effectiveness of new investigational drugs, devices, or treatments in humans. These studies are conducted worldwide for a range of conditions and illnesses. Learn more about clinical research and participating in a study at About Clinical Trials.